Executive Profiles

Executive Roundtable

Leadership

Press Releases

Corporate Communications

Healthcare Access

Patient Education

Telehealth

Direct-to-Consumer

Funding

Partnerships

Emerging Biopharma

Finance

Industry Trends

IR Licensing and Partnerships

Patient Access

Pricing

Strategy

Market Access

Clinical Data

Patient Advocacy

Pharmacovigilance

Medical Affairs

R&D/Clinical Trials

Supply Chain

Sustainability

Technology

Operations

DE&I

Patient Engagement

Global

Legal

Regulatory

Campaigns

DTC Marketing

Medical Education

Sales Effectiveness

Sales & Marketing

News

Academy

Multimedia

Editorial Podcasts

Editorial Videos

Peer Exchange

Profiles in Medicine

Conferences

Conference Coverage

Conference Listing

Publications

Pharmaceutical Executive

Partner Perspectives

Resources

Content Engagement Hubs

E-Books

Events

Webcasts

Whitepapers

Subscribe

Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and leadership to drive success.

About

Advertise

Contact Us

Editorial Board

Editorial Submission Guidelines

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Executive - Leadership, Strategy & Market Access

LinkedIN

Instagram

Facebook

Threads

Bluesky

Spotlight

Latest Executive Roundtables

Asembia 2025 

Topic

Sales and Marketing

1rem

Videos

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a part.

The Threat of Misinformation on Public Health

 podcast episode, UpScriptHealth founder and CEO Peter Ax discusses:

The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications

How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts

How digital health platforms can help potentially offset tariff impacts

The importance of telehealth in ensuring medication availability

Strategic partnerships between digital health platforms and pharma companies to improve patient care and access

Podcasts

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, explores:

How AI can potentially revolutionize patient engagement and adherence

Utilizing patient-level data and predictive modeling

How AI can identify individual needs and preferences

The importance of ethical considerations and data privacy when leveraging AI in healthcare

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Key trends in healthcare communication to build trust between healthcare providers and their patients.

The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value. 

HEOR: From Proving Product Value to Proving Its Own Worth

J&J Aims to Reduce Oncology Care Gaps Through Community Support and Seamless Transitions

, Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discussed how the company is responding to growing challenges in cancer care revealed by its Oncology Care Index. With 76% of healthcare providers reporting feeling overwhelmed by the pace of innovation, the index offers critical insights into the barriers physicians face when translating breakthroughs into clinical practice. Naumovic outlined how J&J is using these findings to drive meaningful support for oncologists—through enhanced research access, community-based care models, responsible integration of AI, and targeted efforts to reduce cognitive burden across the care continuum.

Pharmaceutical Executive: If the Oncology Care Index were revisited two years from now, what progress would you hope to see—and how is J&J working to help realize that vision?

Fast forward a few years, and I’d really like to see measurable progress in the key areas we've identified. First and foremost, I hope to see a decrease in the levels of overwhelm reported—particularly by supporting community oncologists with earlier access to information and research engagement.

We're also focused on improving care transitions for patients across institutions, wherever Johnson & Johnson can play a supportive role. Another important goal is increasing the involvement of advanced practice providers and nurses in care delivery—whether in oncology, urology, or other community settings.

These are all areas we’re actively working on. In the disease areas where Johnson & Johnson is directly involved, I’m optimistic that we’ll see meaningful improvements in how care is delivered—making the process more seamless and straightforward for both physicians and patients.

Johnson & Johnson (J&J) launched the Oncology Care Index to better understand the mounting pressures oncologists face amid rapid innovation—highlighting that 76% of healthcare providers feel overwhelmed. In 2024 alone, the FDA approved 50 new indications and 11 new molecular entities, underscoring the urgent need to translate breakthroughs into practical care. J&J uses the index not as a self-promotional tool but as a catalyst for industry-wide dialogue around care delivery, implementation of innovation, and systemic barriers.

Two insights from the index stood out: the difficulty community oncologists face in accessing clinical research and the fragmentation in the continuum of care as patients transition between treatment centers. To address these, J&J is expanding access to community-based clinical trials and co-developing protocols with community providers, particularly in areas like multiple myeloma and lung cancer. They're also pushing for policy changes that support non-academic trial sites. At the same time, the company is investing in training and infrastructure to ensure continuity of care and appropriate treatment closer to patients’ homes.

J&J sees artificial intelligence (AI) as a major opportunity to alleviate provider burden but acknowledges that true adoption requires collaboration across the ecosystem. The company is leveraging AI to improve trial recruitment and streamline decision-making but stresses the need for open, connected databases and industry-wide alignment.

To combat burnout and cognitive overload, J&J is focused on delivering timely, contextualized education and CME programs, supporting advanced practice providers and nurses, and enhancing patient support services.

Looking ahead, J&J hopes to see decreased provider overwhelm and more seamless integration of innovation into care, driven by empowered community oncologists, improved transitions of care, and greater engagement of frontline healthcare workers in both research and treatment delivery.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is working to ease care transitions, support community oncologists, and reduce overwhelm in cancer treatment delivery.

Video Series

The Role of Patient Advocacy in Shaping AbbVie's Cancer Therapies

, Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discussed the company’s expanding efforts in solid tumors, a space where it is still relatively new compared to its established presence in hematologic cancers. Speaking on the sidelines of the 2025 ASCO Annual Meeting, Valencia outlined AbbVie’s strategy for prioritizing tumor types and investigational therapies within its pipeline, emphasizing a data-driven, patient-centric approach. From recent antibody-drug conjugate (ADC) approvals to promising early signals in rare neuroendocrine tumors, AbbVie is rapidly evolving its oncology footprint with the goal of transforming treatment paradigms and reducing reliance on traditional chemotherapy.

Pharmaceutical Executive: Many of the tumors studied are difficult-to-treat and often have limited options—how does AbbVie integrate patient advocacy and unmet need assessments into early development decisions?

Every time we develop a molecule in oncology—or really in any therapeutic area, but especially oncology—it has to be a partnership. This partnership involves AbbVie, our scientists, clinicians, academic institutions, and importantly, patient advocacy groups. These groups help us truly understand the unmet needs in the field. Beyond traditional endpoints like overall survival and progression-free survival, patient advocacy helps us grasp what really matters to patients.

For example, with our ovarian cancer antibody-drug conjugate (ADC), while we see clear survival benefits compared to chemotherapy, patient groups have highlighted another important advantage: our molecule prevents alopecia. For women battling ovarian cancer, not losing their hair during treatment is a significant benefit. They can maintain their dignity and sense of normalcy through therapy, which is incredibly meaningful.

These insights shape our development plans to ensure no patient is left behind. Another reason we're focusing on neuroendocrine tumors is the substantial unmet need in these rare populations. Our goal is to work closely with patients and advocacy groups to bring effective medicines to them as quickly as possible.

 At the 2025 ASCO meeting, AbbVie highlighted its growing commitment to solid tumors by outlining how it prioritizes development within its oncology pipeline. While historically focused on hematologic malignancies, the company is now building momentum in solid tumors with an emphasis on unmet need, scientific opportunity, and potential for pipeline impact. AbbVie’s three current priority areas in solid tumors are gastrointestinal (especially colorectal), gynecologic (notably ovarian), and lung cancers. Recent approvals, including mirvetuximab for ovarian cancer and Teliso-V (telisotuzumab vedotin) for non–small cell lung cancer (NSCLC), mark significant progress.

Temab-A (and Teliso-V) targets c-Met, a protein overexpressed in multiple cancers, including lung, colorectal, pancreatic, and head and neck cancers. Its broad expression makes c-Met a strong target for tumor-agnostic development, akin to HER2 or PD-1 therapies. AbbVie is exploring this approach with Temab-A in a trial spanning at least seven tumor types, including lung and colorectal cancers being the most advanced.

Another investigational therapy, ABBV-706, targets SEZ6, a lineage marker in neuroendocrine tumors, including small cell lung cancer (SCLC). Data presented at ASCO showed encouraging response rates of 30–50% in rare neuroendocrine tumors—substantially higher than typical chemotherapy response rates. AbbVie plans to expand 706 into late-stage studies for SCLC and explore other neuroendocrine populations.

Patient advocacy is central to AbbVie’s strategy, helping inform development priorities beyond survival endpoints. For example, patient feedback highlighted Elahere’s ability to avoid alopecia as a significant benefit.

Key near-term milestones include pivotal trial launches and data readouts across lung (EGFR-mutant and wild-type NSCLC, SCLC), GI (colorectal and pancreatic), and gynecologic cancers. AbbVie also plans to expand next-generation ADCs, aiming to broaden activity across varying levels of FRα expression and further reduce chemotherapy reliance.

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the development of innovative cancer therapies.

Designing Smarter Interventions with Community Insights

As the healthcare industry sharpens its focus on patient-centered care, addressing social determinants of health, health equity, and literacy has become more critical than ever—particularly for individuals with chronic and rare conditions. During the 

"Speaking Health and Human: Bridging the Gap to Quality Patient Care"

 session, Tiara Green will join industry leaders to explore how barriers to access, education, and navigation of the healthcare system directly influence patient outcomes. In an interview with 

, Green previews the key issues shaping the conversation and why understanding these factors is essential to delivering better, more equitable care.

Pharmaceutical Executive: What are some of the most impactful preventive strategies you've seen that truly bridge the gap in healthcare access?

Early in my career, I worked on projects that involved community health workers. People often ask, "Why community health workers?" The answer is simple—they live in the communities we aim to serve. They reflect the population, understand their challenges, and most importantly, they’re trusted. That trust allows them to bridge the gap in access to care. They help ensure patients get the necessary screenings, and they often connect people to critical resources like job support or food assistance. Their role is essential in reducing disparities and improving outcomes.

PE: How can providers and health systems better incorporate community input when designing preventive or educational interventions?

The key is to involve the community from the very beginning—during the planning phase, not just at the implementation stage. Too often, programs are created without community input and then presented as a finished product. That approach risks missing the mark. By giving the community a voice early on, we can better understand their real needs and tailor interventions that truly resonate and succeed.

During the “Health and Human: Bridging the Gap to Quality Patient Care” session, attendees can expect a thoughtful discussion on how health equity, screening and diagnostic services, and health literacy together influence overall healthcare outcomes. The session will explore how social determinants of health—such as income, education level, and geographic location—directly impact the patient experience, especially for individuals living with rare and chronic conditions. Challenges like limited access to specialized care, difficulty navigating complex healthcare systems, and lower levels of health literacy will be key themes.

The conversation will also highlight effective strategies that have successfully bridged gaps in healthcare access. One major focus will be the role of community health workers, who serve as trusted, relatable figures within their communities. By understanding and representing the populations they serve, these workers can connect individuals to essential screenings, care resources, and social services like employment or food assistance.

Another critical point will center on how healthcare providers and systems can better design preventive and educational interventions by involving community members early in the planning process. Rather than imposing pre-developed programs, incorporating the lived experiences and voices of the target population helps create initiatives that are more relevant, effective, and sustainable.

Finally, looking to the future, the speaker emphasizes that achieving a healthier, more equitable society requires systemic and structural change. Addressing issues at the policy and institutional levels, fostering collaboration between healthcare systems and community-based organizations, and rethinking how care is delivered will be essential to creating lasting improvements in health equity.

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are key to closing persistent gaps in preventive care and healthcare access.

Latest Conference Coverage

Asembia 2025: Designing Smarter Interventions with Community Insights

Bridging Healh Gaps Through Equity and Education 

As the healthcare industry sharpens its focus on patient-centered care, addressing social determinants of health, health equity, and literacy has become more critical than ever—particularly for individuals with chronic and rare conditions. During the 

 session, Tiara Green will join industry leaders to explore how barriers to access, education, and navigation of the healthcare system directly influence patient outcomes. In an interview with 

Pharmaceutical Executive: You will be a part of the ‘Speaking Health and Human: Bridging the Gap to Quality Patient Care’ session. Can you provide a brief synopsis of what to expect during the discussion?

We definitely encourage people to attend the session, but broadly, we'll be exploring the impact of health equity on screening and diagnostic services, as well as the role of health literacy. We’ll discuss how these factors together influence overall health outcomes.

Pharm Exec: How do you see social determinants of health shaping the patient experience, particularly for those with rare or chronic conditions?

Social determinants of health are critical for all patients, but they’re especially important for those living with rare or chronic conditions. We need to consider access to care—how income level, education, and where someone lives affect their ability to get the services they need.

For example, individuals in rural areas—or even in low-income urban communities—may struggle to access healthcare providers, especially specialists. When dealing with rare or chronic conditions, access to specialized care is vital, yet not always available or easy to navigate.

Health literacy also plays a key role. Individuals with lower educational attainment—such as not completing high school or college—may not fully understand how to navigate the healthcare system. Even as professionals, we sometimes find the system difficult to manage. That’s why it’s so important to address these barriers if we want to improve health outcomes.

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Asembia 2025: Bridging Health Gaps Through Equity and Education

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access, and how the industry can ensure that these technologies are used responsibly and equitably.

Ethical Considerations for AI Use in Medication Access

 video interview, Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses "The 2025 Medication Access Report." She highlights gaps in data-sharing and cross-functional collaboration as major bottlenecks that cause delays, rework, and increased patient burden. Chiang shares that only 3% of patients utilize support programs due to a lack of awareness. A large majority of the report's respondents plan to expand funding for patient support programs within the next 5 years due to large number of new therapies expected to come to market.

Pharmaceutical Executive: With the rapid advancement of AI, what are the ethical considerations surrounding its use in medication access, and how can the industry ensure that these technologies are used responsibly and equitably?


Ethical considerations with the use of any technology tool that is going to replace human decision making is something that we are quite focused on as an organization. We believe in responsibility and that AI should only be a complementary tool until we are very confident in the fair and unbiased nature of the AI and the diverse data sets that it’s pulling from.

For today and the near future, we believe the best position for AI is where technology enhances clinical support. The human component of care continues to be the most important element of making sure that the right clinical decisions are made for patients. We want to make sure that AI is used to support, not replace. The human touch in healthcare should persist in the most relevant clinical support services going forward.

We also believe in the protection of private information. Building those diverse data sets while maintaining patient privacy is a critical element to consider as an industry. While thinking about patient privacy, we also must think about transparency in decision making. A patient should know how a decision was made relative to their care. They should fully understand and be able to ask questions about how the process solicited this type of support for them.

The ability to protect privacy and maintain transparency in the decision-making process for patients is a critical factor that the industry needs to think about.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, addresses patient and prescriber expectations for digital health tools.

Balancing Technological & Human Support in Medication Access

Pharmaceutical Executive: The report addresses patient and prescriber expectations for digital health tools. How do you see the balance between technology, including AI, and human support evolving in the context of medication access?


 AI has to bring a fair and unbiased approach when it comes to medication access. The emerging use of AI, which is taking decisions out of the hands of humans and clinicians, is not ideal. It needs to strike the balance of support-not-replace. The same is true for technology and balancing the need for easy, quick digital tools that support patients finding information faster and getting education when they need it most with the need to speak to a human and have more clarity.

The utility of a digital tool when you’re overwhelmed, ill, and don’t have a good support system is where a paradox comes into play.

How do we provide the just-in-time tools for patients with some digital sophistication, while still recognizing that there is going to continue to be a significant need for patients to seek help through a variety of channels? That’s where patient support program engagement comes in. You are able to balance tools for patients who want to use them with patients who want to speak to humans.

Restrictive programs are something I would caution pharma against. There’s not only one way to do things, and there are efficient ways to have human interaction. The industry really needs to look at that. How can we ensure that the right patient gets the right resource? AI can help us understand that fragmentation and the dimensionalization. When there’s complexity with a patient population, AI could begin the journey and know when to pass things to humans.

We need to strike that balance between using AI and identifying when a patient needs to talk to a human.

If you’ve used chatbots and other AI tools that exist today, there’s a point when you refine as much as you possible can and you’re still unsatisfied. We need to have excellent identification through AI of where the journey begins and ends. The technology can only get us so far and we need to offer patients the flexibility to receive the support they need in the manner in which they feel is best for them.

The fair and unbiased approach is going to require significant and diverse data sets. AI is only as good as the information it’s feeding from, so we need to make sure that we as an industry are looking at fair and unbiased data sets that we are making decisions from. Patients and providers also deserve to know how decisions are being made on their behalf. As an industry, that is going to be a challenge to us. Ensuring that we are protecting the privacy of the patient throughout that journey is paramount.

There’s great hope for AI in the ability to get patients to the support they need faster. There is work for the industry to do, however, in creating those fair and unbiased data sets.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses how the industry leverages data and technology to identify and address affordability issues before they become a barrier to patient access.

Proactively Identifying & Addressing Affordability Issues with Predictive Analytics

Pharmaceutical Executive: How can the industry leverage data and technology to proactively identify and address affordability issues before they become a barrier to patient access? What role does predictive analytics play in this?


 The ability to be proactive in identifying and addressing those gaps requires a centralized data system and a greater ecosystem. The ability to leverage data requires that data to be comprehensive. Predictive analytics will run on strong data models, and in order to have those, you need a seamless experience.

How do we capture data along the patient journey, and how do we ensure that predictive analytics will help us analyze that data? It all starts with the ability to streamline the data. If we don’t begin to bring data sources together in real and important ways, we will not be able to properly allocate our resources and spending in pharma. There will be some forecasting and assumptions, but with some real-world data (RWD) integrated.

Think about the addition of an integrated data model with RWD and what that could do for better predictive analytics. Our assumptions would be lowered, and our predictions would be better. We would have optimized predictability for where the funding needs to be directed.

The second piece of that is you have better clinical outcomes if you can identify in advance. You will not have patients walking away from their prescriptions, which continues to be a challenge. We are also seeing significant increases in claims denials. About 73% of claims are denied. What do we do when claims come back denied?

With predictive analytics, there are affordability and co-pay types of expansion. There’s also focus and energy around overturning claim denials. How do we ensure that the claim was denied for righteous reasons? The ability to have all of the data integrated and run it through predictive analytics alongside RWD would help us improve clinical outcomes. Those patients will not be denied medication that they need and rightfully deserve.

Doing all of this more efficiently will remove costs from the ecosystem. There is significant fragmentation in all of the processes. To bring all of that data together to understand the market access for a single brand launch, bio-pharmas must piece together all of that information. Bringing data together and using predictive analytics with strong data models will help these companies do so more efficiently. It will take costs out of the system and speed patients onto the right medications. Healthcare providers will also spend less time waiting for the patient to get approved.

Kimberley Chiang, vice president of biopharma commercial solutions, CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.

The 2025 Medication Access Report: Biggest Bottlenecks for Patients

 video interview, Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses "The 2025 Medication Access Report.

 She highlights gaps in data-sharing and cross-functional collaboration as major bottlenecks that cause delays, rework, and increased patient burden. Chiang shares that only 3% of patients utilize support programs due to a lack of awareness. A large majority of the report's respondents plan to expand funding for patient support programs within the next 5 years due to large number of new therapies expected to come to market. The report emphasizes the need for interoperability to streamline data and improve patient outcomes.

Pharmaceutical Executive: "The 2025 Medication Access Report" highlights significant fragmentation due to gaps in data-sharing and cross-functional collaboration. Can you elaborate on the most critical areas where these gaps are causing the biggest bottlenecks for patients? Specifically, what are the tangible effects you've observed on patient timelines and outcomes?


The lack of cross-functional collaboration in our industry adds fragmentation, and the seamlessness of the flow of data and the patient experience is impacted. Whenever we impact seamlessness, we impact the data that is arriving to help us make decisions or anticipate gaps in patient care. It causes delays, rework, and for the burden to fall on the patient to piece together all the elements to find the best way to cover some of the barriers that they’re experiencing in their own healthcare ecosystem.

The industry needs a cohesive and efficient approach that takes cost out of the system and adds data at the right time to help HCPs make the right decisions. We need to get out of our silos because we’re still in our own way. The lack of a clear view drives delays, creates barriers, and doesn’t look at the holistic needs of the patient.

For example, pharmacies and providers see certain needs, and pharma is paying for patient support programs to provide other needs for patients. However, we’re not talking to each other, and that’s where the challenge lies. If we’re looking for the best outcomes for patients and the urgency to get them the medications they need quickly and efficiently with all the education and support for the patient journey, we need to improve integration.

The second element is the knowledge gap. Forty-six percent and 52% of providers don’t know what’s out there for patients. They may be able to identify a gap, but they don’t know where to go to fill that gap. Therefore, the pieces still don’t get put together in that puzzle for the patient and causes delays in looking up what’s available for that patient in their community.

The knowledge gap worsens the delay and puts the burden back on the patient to put together the pieces of their healthcare ecosystem themselves.

The pharma industry is committed to increasing the funding for patient-support programs. But if patients don’t know about them, the utilization stays at about 3%. The majority of the biopharma customers we talked to said that in 5 years, they plan to expand support and funding for these programs. That’s based on the fact that important new therapies are coming to market in the next 5 years and 75% of them have increased complexity because they’re in the specialty realm.

Complexity drives gaps and needs. If we don’t bring this ecosystem together and have data sharing across the portfolio to reduce fragmentation, we are going to continue to see delays which effectively reduce outcomes for patients.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, highlights gaps in data sharing and cross-functional collaboration as major bottlenecks that are causing delays, rework, and increased patient burden.

Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's recent partnership with Pfizer is impacting drug access.

Insights on UpScriptHealth’s Recent Pfizer Partnership & Its Impact on Drug Access

 Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry, highlighting that tariffs will initially affect pharmaceutical companies, particularly those dealing with branded medications and generics. He notes that tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts. Digital health platforms like UpScriptHealth aim to reduce friction and costs in healthcare, potentially offsetting tariff impacts. Ax emphasizes the importance of telehealth in ensuring medication availability and the strategic partnerships between digital health platforms and pharma companies to improve patient care and access. He also praises Pfizer's approach to delivering comprehensive care rather than just selling medications.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's recent partnership with Pfizer is impacting drug access.

Patient Advocacy

Latest News

More News